News | Prostate Cancer | June 21, 2023

POSLUMA is now commercially available in multiple U.S. radiopharmacies, with nationwide availability by end of June 2023 

POSLUMA is now commercially available in multiple U.S. radiopharmacies, with nationwide availability by end of June 2023

POSLUMA (flotufolastat F 18) PET/CT image showing uptake in the prostate gland, consistent with primary prostate cancer Photo courtesy of Blue Earth Diagnostics 


June 21, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, and PETNET Solutions Inc, A Siemens Healthineers Company, announced the commercial availability of POSLUMA (flotufolastat F 18) in the United States. POSLUMA (formerly referred to as to as 18F-rhPSMA-7.3) is an optimized, high-affinity radiohybrid (rh) Prostate-Specific Membrane Antigen (PSMA)-targeted PET imaging agent. It is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy or with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. POSLUMA was approved by the U.S. Food and Drug Administration on May 25, 2023. 

POSLUMA is now commercially available through multiple radiopharmacies of PETNET Solutions, the primary manufacturer and commercial distributor for Blue Earth Diagnostics in the United States. By the end of June 2023, commercial production across the country will be underway at the 31 PETNET radiopharmacies Blue Earth Diagnostics included in its New Drug Application for POSLUMA, marking a record number of sites authorized for the manufacturing of a radiopharmaceutical upon its initial FDA approval. Additional PETNET sites are expected to manufacture POSLUMA before the end of the summer. 

“We are pleased to make POSLUMA widely available across the United States for use in men with newly diagnosed or suspected recurrence of prostate cancer, and hope that this will make a real difference to physicians and their patients,” said David E. Gauden, D.Phil., Chief Executive Officer of Blue Earth Diagnostics Ltd. “Our product introduction plan for POSLUMA includes practical education programs for physicians and staff at imaging centers to educate them on the appropriate use of POSLUMA, including image acquisition and reader training programs to help ensure the best information is available to inform patient care. In addition, we are actively communicating with Medicare carriers, Medicare Advantage Plans, private insurers and radiology benefit managers to help them understand the utility and value of POSLUMA, so that they will cover these procedures appropriately.” 

Dr. Gauden continued, “It is an ongoing pleasure to continue working with PETNET Solutions. We have a long-standing, productive relationship based on our seven-year success with Axumin (fluciclovine F 18). Our companies share a passion for PET molecular imaging, and for providing imaging tools to help inform the management of patients across the prostate cancer care continuum.” 

“As the main manufacturer and distributor of POSLUMA to imaging centers in the United States, PETNET Solutions is proud to continue our longstanding commercial relationship with Blue Earth Diagnostics, which began in 2015 when we became a commercial supplier of Axumin,” said Barry Scott, Head of PETNET Solutions Inc. “With our large national network of cyclotron-equipped radiopharmacies, we are well-positioned to provide broad access to POSLUMA, as well as a wide range of other novel PET biomarkers that facilitate precision medicine for healthcare providers across the country.” 

Blue Earth Diagnostics and PETNET Solutions welcome visitors to the upcoming Society of Nuclear Medicine and Molecular Imaging(SNMMI) Annual Meeting in Chicago, June 24-27, 2023, to visit their exhibit booths. Blue Earth Diagnostics is at Booth 6025 and PETNET Solutions is at Booth 6075. 

For more information: www.blueearthdiagnostics.com 

 

Find more SNMMI conference coverage here 

 

Related Prostate Cancer Content: 

U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer 

Blue Earth Diagnostics Highlights Upcoming Presentation of Additional Results from Investigational Phase 3 LIGHTHOUSE Study 
Blue Earth Diagnostics Announces Efficacy and Safety Results from Phase 3 LIGHTHOUSE Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Newly Diagnosed Prostate Cancer  
Blue Earth Diagnostics Announces Results on Clinical Factors Impacting Detection Rates from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer  
Independent Clinical Studies Published Regarding Performance of Axumin (Fluciclovine F 18) PET Imaging in Patients with Recurrent Prostate Cancer Undergoing Androgen Deprivation Therapy (ADT)     
Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA     
Blue Earth Diagnostics Announces Key Results from Phase 3 SPOTLIGHT Study of 18F-rhPSMA-7.3     
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT     
Blue Earth Diagnostics Announces Dosing of Initial Patient in Phase 3 REVELATE Clinical Trial of 18F-Fluciclovine PET Imaging for Detection of Recurrent Brain Metastases     
Blue Earth Diagnostics Highlights Presentations on Axumin (Fluciclovine F 18) and 18F-Fluciclovine at ASTRO21 


Related Content

News | Nuclear Imaging

June 20, 2024 — GE HealthCare joined the world’s top medical and academic institutions at the Society of Nuclear ...

Time June 20, 2024
arrow
News | Radiation Therapy

June 19, 2024 — RaySearch Laboratories AB announced a milestone in radiotherapy technology where RaySearch’s RayStation ...

Time June 19, 2024
arrow
News | Artificial Intelligence

June 17, 2024 — Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care ...

Time June 17, 2024
arrow
News | Proton Therapy

June 14, 2024 — Atlantic Health System, an integrated health care system setting standards for quality health care in ...

Time June 14, 2024
arrow
News | PET Imaging

June 14, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Time June 14, 2024
arrow
News | PET-CT

June 13, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Time June 13, 2024
arrow
News | Radiology Business

June 12, 2024 — Cathy Sue Cutler, PhD, FSNMMI, chair of the Isotope Research and Production Department at Brookhaven ...

Time June 12, 2024
arrow
News | SPECT-CT

June 11, 2024 — A newly developed radiotracer can generate high quality and readily interpretable images of cardiac ...

Time June 11, 2024
arrow
News | PET Imaging

June 11, 2024 — A new ultra-high-performance brain PET system allows for the direct measurement of brain nuclei as never ...

Time June 11, 2024
arrow
News | Radiology Business

June 10, 2024 — Jean-Luc C. Urbain, MD, PhD, FASNC, professor of Radiology/Nuclear Medicine and Medicine, has been named ...

Time June 10, 2024
arrow
Subscribe Now